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Monosubstituted alkenyl amino acids for peptide
‘‘stapling’’†
David J. Yeo,ab Stuart L. Warrinerab and Andrew J. Wilson*ab
Alkenylglycine amino acids were assessed as potential candidates
for hydrocarbon stapling and shown to be eﬀective in stapling of
the BID BH3 peptide.
The elaboration of approaches to modulate protein–protein
interactions (PPIs) is a highly sought after goal in contemporary
chemical biology and drug discovery,1,2 with significant effort
focused on a-helix mediated PPIs.3 In this regard, constrained
peptides4–9 have emerged as promising candidates for PPI inhibition
given they are, in principle, able to reproduce exactly the pharmaco-
phore of the template ligand, and have a range of enhanced
properties. Introduction of constraints reduces the degree of freedom
within a polypeptide backbone and if positioned correctly promotes
the biologically active conformation and more potent binding to
target receptors. Typically, constraining a peptide confers greater
resilience to proteolytic digestion, since a peptide must unfold in
order to fit into a protease active site,10 and, in a number of instances
has been shown to assist cellular uptake and activity.11 Synthetic
approaches include functionalisation of peptides with azide–alkyne
‘click’ handles,12 lactam bridges,7 hydrogen bond surrogates13 and
metathesis derived hydrocarbon ‘staples’. All-carbon hydrocarbon
stapling, pioneered by Grubbs14 and Verdine,15 is continuing to grow
in popularity. During peptide synthesis, an unnatural a,a-disub-
stituted amino acid with an alkene tether is incorporated at
i, i + 4, or i, i + 7 positions and metathesised catalytically affording
a covalent crosslink on one face of the peptide.15–17 Following
evaluation of cross-link length, positioning and helix-stabilising
propensities using RNAseA,15 the use of hydrocarbon stapling for
inhibition of PPIs within the B-cell lymphoma (BCL-2) family,18–20
the NOTCH pathway,21 p53–hDM2(X) interactions11,22 caspase PPIs23
and estrogen receptor–co-activator interactions24 has been described.
Recently, a stapled peptide has entered phase I clinical trials.25 In the
course of our ongoing efforts to develop inhibitors of PPIs using
a-helix mimetics,26 we became interested in making comparative
studies with other ligand classes and sought to develop ‘‘stapled’’
peptides. Our initial efforts relied upon synthesis of the requisite
a,a0-disubstituted alkenyl amino acids – a synthetic sequence which
we found to be temperamental in our hands. Thus we asked the
question – can similar effects be achieved with monosubstituted
a-alkenyl amino acids? Herein we illustrate that such a modification
indeed serves as an effective staple and illustrate that multiple
biophysical properties are comparable to peptides stapled with
a,a0-disubstituted amino acids.
Given our prior work,26 we initially sought to test the mono-
substituted amino acid as a constraint using p53–hDM2 as amodel
PPI, however initial attempts to select suitable positions in which to
incorporate a staple afforded a peptide with lower binding than the
unstapled peptide (see ESI†); we were not entirely surprised by this
given the extensive work by the Verdine group on identifying
optimal stereochemistry and chain length of the disubstituted
amino acids for introduction of peptide staples at different posi-
tions in a sequence.15,17 We therefore resorted to the BCL-2 family
of PPIs as a model system (Fig. 1a), following the prior work on
in vivo apoptosis of leukaemia xenografts using hydrocarbon
stapled BID BH3 peptides.18 The BID BH3 peptide is a region of
the pro-apoptotic BID protein which belongs to the family of BCL-2
proteins that regulate apoptotic pathways.27–30 The BH3 region of
BID is an amphiphilic a-helix, which binds into a hydrophobic
groove within the multidomain anti-apoptotic members of BCL-2
family members.31 The synthesis of (S)-pentenylglycine has
previously been described32 following the method developed by
Belokon and co-workers for synthesis of non-natural amino acids.33
Our group have successfully utilised this method in other work34
and applied it here (Fig. 1b and ESI†). For a full comparison, we
also synthesized the original disubstituted amino acid (see ESI†)15
and incorporated this, the monosubstituted amino acid and
aminoisobutyric acid (Aib) at appropriate positions in the BID
sequence which were obtained using standard Fmoc solid phase
peptide synthesis protocols using Rink Amide MBHA resin to
afford C-terminally amidated peptides (Fig. 1c). Alkenyl amino acid
containing peptides were subjected to olefin metathesis to generate
stapled peptides with the un-metathesised variants retained as
controls (not shown, see ESI† for details).
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The helix stabilising properties of each mutation to the sequence
were assessed using circular dichroism (Fig. 2a). The spectra clearly
illustrate that the monosubstituted and disubstituted amino acids
promote helicity with minima at 208 and 222 nm, compared to a
random coil for the wild type and intermediate level of helicity for
the Aib substituted sequence. BID-WT, BID-Aib, BID-DM, BID-MM,
gave a-helicities of 12%, 31%, 80% and 73% respectively. With this
result in hand, enzymatic degradation experiments with trypsin were
performed using HPLC to determine the extent of resistance to
proteolysis upon stapling. Trypsin selectively hydrolyses the peptide
bond to the C-terminal side of basic residues, lysine and arginine, of
which three are present in the BID BH3 sequence. HPLC analysis
showed that the full peptide was degraded into smaller fragments
during the experiment, and plotting ln S against time indicated
first order kinetics with respect to the substrate (Fig. 2b). BID-WT,
BID-Aib, BID-DM, BID-MM were found to be 5%, 12%, 38% and
35% intact respectively after 90 minutes, indicating that stapling the
peptide confers significant resistance to proteolytic degradation, but
again that little diﬀerence exists between the monosubstituted
and disubstituted amino acid staples. Finally, a consequence of
restricting the conformational plasticity of a peptide is an increase in
binding aﬃnity of the peptide to its protein partner. To test the
binding capabilities of the peptides, we used a fluorescence aniso-
tropy based competition assay to follow the displacement of BODIPY
labelled BAK from the BH3 binding groove of BCL-xL. Briefly, a
BODIPY labelled BAK was shown in our hands to exhibit a Kd of
4 nM towards BCL-xL in the forward titration experiment (see ESI†).
Displacement of this tracer peptide under appropriate conditions
aﬀorded IC50’s as shown in Fig. 2c. Curiously, none of the modifica-
tions result in significant improvement in inhibitory potency (IC50’s
for BID-WT, BID-Aib, BID-DM, BID-MM were found to be 1.44
(0.05), 1.14 (0.02), 1.15 (0.04) and 0.62 (0.02) mM). The Hill
coeﬃcients in the curves for both stapled peptides are noteworthy
and point to a more complex equilibrium than a standard 1 :1
competition. This does not arise due to interaction between the
peptide tracer (BODIPY-BAK) and the competitor peptides (as we
observed previously for a p53–hDM2 anisotropy assay)35 as we did
not detect changes in anisotropy upon titration of BODIPY-BAK with
Fig. 1 (a) Structure of the BCL-xL in complex with a BAK peptide (PDB-ID:1 BXL);
(b) abbreviated synthetic route to a-pentenyl glycine (c) sequence of the BID BH3
peptides, BID-WT, BID-Aib, BID-DM and BID-MM. (NL = norleucine substitution for
wild type Met)18 Fig. 2 Biophysical data for the BID peptides; BID-WT (black), BID-AIB (purple),
BID-DM (red), BID-MM (blue), (a) circular dichroism shows enhanced helicity after
stapling; (b) trypsin proteolysis studies. (c) Fluorescence anisotropy competition
assays for the modified peptides.
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BID peptides. More detailed biophysical and structural studies are in
progress.
A significant feature of the stapling approach is the supposed
enhanced cellular uptake conferred upon a peptide as a result of
stapling, however recent evidence has indicated that this is a
complex issue with experimental conditions playing a significant
role.36 Similarly in certain instances, whilst stapling does not
appear to improve potency or the propensity of a peptide to adopt
its bioactive conformation in comparison to other modifications, it
can result in improved in cellulo PPI inhibition.11 The current
preliminary results thus contribute to the growing body of research
on peptide stapling; from a biophysical perspective, a modification
to any given peptide sequence e.g. the use of b-amino acids37,38
which tips the balance in favour of helix nucleation39,40 is what
is required for enhanced proteolytic stability and a preferred
bioactive conformation. In contrast, cell uptake and function need
to be considered and optimised separately.41
In summary, we have shown that a-alkenyl substituted amino
acids act as eﬀective amino acids for peptide stapling and demon-
strate that they can lead to comparable enhancement of proteolytic
stability, enhancement of helical propensity and similar eﬃciency
compared to peptides stapled with an a,a0-disubstituted variant
when applied to the BID BH3 helix and its inhibition of BCL-xL/
BAK as a model PPI. This modified amino acid is less sterically
encumbered than disubstituted amino acids and may facilitate
synthesis and therefore studies of stapled peptides. Our future
work will focus on structural and biophysical measurements on
this and other sequences in addition tomore systematic studies on
cellular behaviour of constrained peptides.
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Huscroft (HPLC), Tanya Marinko-Covell (HRMS) and Prof. Sheena
Radford for useful discussions.
Notes and references
1 S. Surade and T. L. Blundell, Chem. Biol., 2012, 19, 42–50.
2 A. D. Thompson, A. Dugan, J. E. Gestwicki and A. K. Mapp, ACS
Chem. Biol., 2012, 7, 1311–1320.
3 V. Azzarito, K. Long, N. S. Murphy and A. J. Wilson, Nat. Chem.,
2013, 5, 161–173.
4 S. K. Sia, P. A. Carr, A. G. Cochran, V. N. Malashkevich and P. S. Kim,
Proc. Natl. Acad. Sci. U. S. A., 2002, 99, 14664–14669.
5 A. K. Galande, K. S. Bramlett, J. O. Trent, T. P. Burris, J. L. Wittliﬀ
and A. F. Spatola, ChemBioChem, 2005, 6, 1991–1998.
6 L. K. Henchey, A. L. Jochim and P. S. Arora, Curr. Opin. Chem. Biol.,
2008, 12, 692–697.
7 R. S. Harrison, N. E. Shepherd, H. N. Hoang, G. Ruiz-Go´mez,
T. A. Hill, R. W. Driver, V. S. Desai, P. R. Young, G. Abbenante and
D. P. Fairlie, Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 11686–11691.
8 A. B. Mahon and P. S. Arora, Chem. Commun., 2012, 48, 1416–1418.
9 P. Wysoczanski, R. J. Mart, E. J. Loveridge, C. Williams, S. B. M.
Whittaker, M. P. Crump and R. K. Allemann, J. Am. Chem. Soc., 2012,
134, 7644–7647.
10 P. K. Madala, J. D. A. Tyndall, T. Nall and D. P. Fairlie, Chem. Rev.,
2010, 110, PR1–PR31.
11 C. J. Brown, S. T. Quah, J. Jong, A. M. Goh, P. C. Chiam, K. H. Khoo,
M. L. Choong, M. A. Lee, L. Yurlova, K. Zolghadr, T. L. Joseph,
C. S. Verma and D. P. Lane, ACS Chem. Biol., 2012, 8, 506–512.
12 S. A. Kawamoto, A. Coleska, X. Ran, H. Yi, C.-Y. Yang and S. Wang,
J. Med. Chem., 2011, 55, 1137–1146.
13 A. Patgiri, K. K. Yadav, P. S. Arora and D. Bar-Sagi, Nat. Chem. Biol.,
2011, 7, 585–587.
14 H. E. Blackwell and R. H. Grubbs, Angew. Chem., Int. Ed., 1998, 37,
3281–3284.
15 C. E. Schafmeister, J. Po and G. L. Verdine, J. Am. Chem. Soc., 2000,
122, 5891–5892.
16 Y.-W. Kim, P. S. Kutchukian and G. L. Verdine, Org. Lett., 2010, 12,
3046–3049.
17 Y.-W. Kim, T. N. Grossmann and G. L. Verdine, Nat. Protocols, 2011,
6, 761–771.
18 L. D. Walensky, A. L. Kung, I. Escher, T. J. Malia, S. Barbuto,
R. D. Wright, G. Wagner, G. L. Verdine and S. J. Korsmeyer, Science,
2004, 305, 1466–1470.
19 M. L. Stewart, E. Fire, A. E. Keating and L. D. Walensky, Nat. Chem.
Biol., 2010, 6, 595–601.
20 J. L. LaBelle, S. G. Katz, G. H. Bird, E. Gavathiotis, M. L. Stewart,
C. Lawrence, J. K. Fisher, M. Godes, K. Pitter, A. L. Kung and
L. D. Walensky, J. Clin. Invest., 2012, 122, 2018–2031.
21 R. E. Moellering, M. Cornejo, T. N. Davis, C. D. Bianco, J. C. Aster,
S. C. Blacklow, A. L. Kung, D. G. Gilliland, G. L. Verdine and
J. E. Bradner, Nature, 2009, 462, 182–188.
22 S. Baek, P. S. Kutchukian, G. L. Verdine, R. Huber, T. A.
Holak, K. W. Lee and G. M. Popowicz, J. Am. Chem. Soc., 2011,
134, 103–106.
23 K. L. Huber, S. Ghosh and J. A. Hardy, Pept. Sci., 2012, 98, 451–465.
24 C. Phillips, L. R. Roberts, M. Schade, R. Bazin, A. Bent, N. L. Davies,
R. Moore, A. D. Pannifer, A. R. Pickford, S. H. Prior, C. M. Read,
A. Scott, D. G. Brown, B. Xu and S. L. Irving, J. Am. Chem. Soc., 2011,
133, 9696–9699.
25 Y. Chang, B. Graves, V. Guerlavais, L. Vassilev, K. Packman,
K. Olson, A. Annis, C. Tovar, H. Nash and T. Sawyer, Eur. J. Cancer,
2012, 48(Suppl 6), 68–69.
26 V. Azzarito, P. Prabhakaran, A. I. Bartlett, N. S. Murphy, M. J. Hardie,
C. A. Kilner, T. A. Edwards, S. L. Warriner and A. J. Wilson, Org.
Biomol. Chem., 2012, 10, 6469–6472.
27 N. N. Danial and S. J. Korsmeyer, Cell, 2004, 116, 205–219.
28 L. Chen, S. N. Willis, A. Wei, B. J. Smith, J. I. Fletcher, M. G. Hinds,
P. M. Colman, C. L. Day, J. M. Adams and D. C. S. Huang, Mol. Cell,
2005, 17, 393–403.
29 M. Certo, V. D. G. Moore, M. Nishino, G. Wei, S. Korsmeyer,
S. A. Armstrong and A. Letai, Cancer Cell, 2006, 9, 351–365.
30 P. E. Czabotar, D. Westphal, G. Dewson, S. Ma, C. Hockings,
W. D. Fairlie, E. F. Lee, S. Yao, A. Y. Robin, B. J. Smith, D. C.
S. Huang, R. M. Kluck, J. M. Adams and P. M. Colman, Cell, 2013,
152, 519–531.
31 M. Sattler, H. Liang, D. Nettesheim, R. P. Meadows, J. E. Harlan,
M. Eberstadt, H. S. Yoon, S. B. Shuker, B. S. Chang, A. J. Minn,
C. B. Thompson and S. W. Fesik, Science, 1997, 275, 983–986.
32 A. D. Bautista, J. S. Appelbaum, C. J. Craig, J. Michel and
A. Schepartz, J. Am. Chem. Soc., 2010, 132, 2904–2906.
33 Y. N. Belokon, A. G. Bulychev, S. V. Vitt, Y. T. Struchkov,
A. S. Batsanov, T. V. Timofeeva, V. A. Tsyryapkin, M. G. Ryzhov,
L. A. Lysova, V. I. Bakhmutov and V. M. Belikov, J. Am. Chem. Soc.,
1985, 107, 4252–4259.
34 G. W. Preston, S. E. Radford, A. E. Ashcroft and A. J. Wilson, Anal.
Chem., 2012, 84, 6790–6797.
35 J. P. Plante, T. Burnley, B. Malkova, M. E. Webb, S. L. Warriner,
T. A. Edwards and A. J. Wilson, Chem. Commun., 2009, 5091–5093.
36 T. Okamoto, K. Zobel, A. Fedorova, C. Quan, H. Yang,
W. J. Fairbrother, D. C. S. Huang, B. J. Smith, K. Deshayes and
P. E. Czabotar, ACS Chem. Biol., 2012, 8, 297–302.
37 Y.-H. Shin, D. E. Mortenson, K. A. Satyshur, K. T. Forest and
S. H. Gellman, J. Am. Chem. Soc., 2013, 135, 8149–8152.
38 M. D. Boersma, H. S. Haase, K. J. Peterson-Kaufman, E. F. Lee,
O. B. Clarke, P. M. Colman, B. J. Smith, W. S. Horne, W. D. Fairlie
and S. H. Gellman, J. Am. Chem. Soc., 2011, 134, 315–323.
39 J. M. Scholtz and R. L. Baldwin, Annu. Rev. Biophys. Biomol. Struct.,
1992, 21, 95–118.
40 A. Patgiri, S. T. Joy and P. S. Arora, J. Am. Chem. Soc., 2012, 134,
11495–11502.
41 A. Muppidi, K. Doi, S. Edwardraja, E. J. Drake, A. M.
Gulick, H.-G. Wang and Q. Lin, J. Am. Chem. Soc., 2012, 134,
14734–14737.
ChemComm Communication
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
4 
Se
pt
em
be
r 2
01
3.
 D
ow
nl
oa
de
d 
on
 1
2/
09
/2
01
3 
20
:4
4:
34
. 
View Article Online
